Document Detail

Daily 500 mg Valacyclovir Is Effective for Prevention of Varicella Zoster Virus Reactivation in Patients with Multiple Myeloma Treated with Bortezomib.
MedLine Citation:
PMID:  23225448     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: In patients with multiple myeloma (MM), bortezomib is associated with a significant risk of Varicella zoster virus (VZV) reactivation. There are some reports that acyclovir reduces the risk of VZV reactivation. We assessed whether VZV reactivation could be reduced by using prophylactic valacyclovir at a dose of 500 mg daily.
PATIENTS AND METHODS: We retrospectively evaluated 32 patients with MM who received bortezomib and valacyclovir prophylaxis at the Kanazawa Medical University Hospital. Patients received valacyclovir prophylaxis orally at a dose of 500 mg daily, without cessation during bortezomib treatment.
RESULTS: The median age was 69 years (range=45-90 years). Fifteen patients were male and seventeen were female. The median bortezomib dose was 37.0 mg/m(2) (range=5.2-167.6 mg/m(2)). All patients also received corticosteroids. The median duration of valacyclovir prophylaxis was 301 days (range=24-1206 days) and the median valacyclovir dose was 150.5 g (range=12-603 g). VZV reactivation developed in only one patient during valacyclovir prophylaxis. VZV reactivation did not develop in three patients who had a past history of VZV reactivation without valacyclovir prophylaxis. Adverse events over grade 3 associated with valacyclovir were not observed.
CONCLUSION: Valacyclovir at a dose of 500 mg daily appears to be effective at preventing VZV reactivation and was well-tolerated by patients with MM who received bortezomib.
Toshihiro Fukushima; Tomomi Sato; Takuji Nakamura; Haruka Iwao; Akio Nakajima; Miyuki Miki; Tomoyuki Sakai; Takafumi Kawanami; Toshioki Sawaki; Yoshimasa Fujita; Masao Tanaka; Yasufumi Masaki; Toshiro Okazaki; Hideo Nakajima; Yoshiharu Motoo; Hisanori Umehara
Related Documents :
24019818 - Evaluation of anticonvulsant effect of two novels 4-[1-(4-fluorobenzyl)- 5-imidazolyl] ...
20946718 - Effect of the single-dose of nicotine-administration on the brain bioelectrical activit...
23575478 - Phase i study of the hedgehog pathway inhibitor ipi-926 in adult patients with solid tu...
22095778 - Toxicokinetic study of melamine in the presence and absence of cyanuric acid in rats.
22371898 - No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleo...
15542168 - Sensitivity of treatment plan optimisation for prostate cancer using the equivalent uni...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5437-40     Citation Subset:  IM    
Department of Hematology and Immunology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Low-grade Central Osteosarcoma of the Metatarsal Bone: A Clinicopathological, Immunohistochemical, C...
Next Document:  Atypical hyperplasia of the breast: the black hole of routine breast cancer screening.